Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.
The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory disease. Several of the antibodies have been investigated in combination with each other as well as with conventional chemotherapeutic regimens. Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.
Sikder
Manzurul A
MA
James P. Wilmot Cancer Center, Division of Hematology-Oncology, University of Rochester, 601 Elmwood Avenue,Box 704, Rochester, NY 14642, USA.
Friedberg
Jonathan W
JW
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; C550338:PRO131921 monoclonal antibody; C448700:epratuzumab; D000074323:Alemtuzumab; D000069283:Rituximab; C533411:ocrelizumab; C493846:veltuzumab; C527517:ofatumumab; C437823:galiximab; C543331:dacetuzumab